Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser

References

• Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973;3:1–54. doi:10.1016/0049-0172(73)90034-6.
   PubMedGoogle Scholar
• Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39:257–268. doi:10.1016/j.semarthrit.2008.10.007.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythemtosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42:1785–1796. doi:10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#.
   PubMedGoogle Scholar
• Bertsias G, Ioannidis JP, Boletis J, et al. Task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205. doi:10.1136/ard.2007.070367.
   PubMed Web of Science ®Google Scholar
• Hahn. BH. Belimumab for systemic lupus erythematosus. N Engl J Med. 2013;368(16):1528–1535. doi:10.1056/NEJMct1207259.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE). Arthritis Rheumatol. 2015;67(Suppl10):S3859. Abstract 3218.
   Google Scholar
• Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169:107–121.
   PubMed Web of Science ®Google Scholar
• Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010;12(2):111. doi:10.1186/ar2976.
   PubMed Web of Science ®Google Scholar
• Fattah Z, Isenberg DA. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. Expert Opin Biol Ther. 2014;14(3):311–326. doi:10.1517/14712598.2014.871256.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA. Lupus clinical trials: medication failure or failure in study design. Rev Bras Reumatol. 2011;51(5):410–411.
   PubMedGoogle Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453–2459. doi:10.1002/art.23678.
   PubMed Web of Science ®Google Scholar
• Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol. 2011;24(1):98–107. doi:10.1038/modpathol.2010.184.
   PubMed Web of Science ®Google Scholar
• Xin G, Shi W, Xu LX, et al. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2013;26(4):683–690. doi:10.5301/jn.5000218.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Moretti M, et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J. 2008;2:38–43. doi:10.2174/1874312900802010038.
   PubMedGoogle Scholar
• Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195–200. doi:10.1084/jem.20041674.
   PubMed Web of Science ®Google Scholar
• Hedegaard CJ, Sellebjerg F, Krakauer M, et al. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler. 2011;17(5):567–577. doi:10.1177/1352458510393771.
   PubMed Web of Science ®Google Scholar
• Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol. 2007;68(7):586–591. doi:10.1016/j.humimm.2007.03.010.
   PubMed Web of Science ®Google Scholar
• Sène D, Limal N, Ghillani-Dalbin P, et al. Hepatitis C virus-associated B-cell proliferation-the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology. 2007;46(1):65–69. doi:10.1093/rheumatology/kel177.
   PubMed Web of Science ®Google Scholar
• Schneeweis C, Rafalowicz M, Feist E, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28(Suppl57):62–66.
   PubMedGoogle Scholar
• Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007;13(19):5903–5909. doi:10.1158/1078-0432.CCR-07-0753.
   PubMed Web of Science ®Google Scholar
• Fragioudaki M, Tsirakis G, Pappa CA, et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leukemia Research. 2012;36:1004–1008. doi:10.1016/j.leukres.2012.03.012.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107–6114. doi:10.1158/1078-0432.CCR-07-1290.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-2.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013;72(9):1461–1468. doi:10.1136/annrheumdis-2012-202775.
   PubMed Web of Science ®Google Scholar
• Raje N, Faber EA, Richardson PG, et al. Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. Blood. 2012;120(21):abstract 447.
   Google Scholar
• Shaw M, Trapp R, Del Giudice J, et al. The effects of repeated doses of briobacept (br3-fc) in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):87.
   Google Scholar
• Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138. doi:10.1182/blood-2013-10-535088.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015. doi:10.1136/annrheumdis-2013-205067.
   Web of Science ®Google Scholar
• Belouski SS, Wallace D, Weisman M, et al. Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus. Cytometry B Clin Cytom. 2010;78(1):49–58. doi:10.1002/cyto.b.20482.
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–1178. doi:10.1002/art.24699.
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51. doi:10.1002/art.24698.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. Group, BLISS-76 Study. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.30613.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9. doi:10.1136/annrheumdis-2011-200937.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015. epub ahead of print. (annrheumdis-2015-207653). doi:10.1136/annrheumdis-2015-eular.1195.
   Web of Science ®Google Scholar
• Merrill JT, Van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III. Ann Rheum Dis. 2015 2015 Aug 20;pii. annrheumdis-2015-207654 doi:10.1136/annrheumdis-2015-207654. epub ahead of print. (annrheumdis-2015-207654)
   Web of Science ®Google Scholar
• Furie RA, Leon G, Ramiterre EB, et al. for the PEARL-SC Study. A Phase 2, randomized, placebo-controlled evaluation of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus. Ann Rheum Dis. 2015;74(9):1667–1675. doi:10.1136/annrheumdis-2013-205144.
   PubMed Web of Science ®Google Scholar
• Furie RA, Thomas M, Chu A, et al. Effects of chronic treatment with blisibimod, an inhibitor of B cell activating factor, on renal and inflammation biomarkers in patients with systemic lupus erythematosus: observations from the placebo-controlled PEARL-SC and open-label extension studies. Arthritis Rheum. 2013;65(Suppl10):1604.
   Google Scholar
• Petri M, Martin RS, Hislop C, et al. effects of blisibimod, an inhibitor of b cell activating factor, on patient reported outcomes and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2014;65(Suppl 10):S123.
   Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi:10.1186/ar3738.
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61–72. doi:10.1002/art.23178.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793–1803. doi:10.1002/art.30373.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233. doi:10.1002/art.27233.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Group, LUNAR Investigator. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi:10.1002/art.34359.
   PubMed Web of Science ®Google Scholar
• Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology. 2012;51(3):476–481. doi:10.1093/rheumatology/ker337.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Miyasaka N, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 2016;26(1):80–86. doi:10.3109/14397595.2015.1060665.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782. doi:10.1136/annrheumdis-2012-201940.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Wallace DJ, Furie R, et al. efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized, placebo-controlled trials. Arthritis Rheumatol. 2015;67(Suppl 10):S3933. Abstract 4L.
   PubMed Web of Science ®Google Scholar
• Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol. 2003;30(2):253–257. doi:10.1053/sonc.2003.50057.
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–475. doi:10.1038/nri844.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475–3486. doi:10.1002/art.11354.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases-positive and adverse effects. Arthritis Res Ther. 2014;16(Suppl 2):S2. doi:10.1186/ar4686.
   PubMedGoogle Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3(9):822–829. doi:10.1038/ni829.
   PubMed Web of Science ®Google Scholar
• Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97(1):198–204.
   PubMed Web of Science ®Google Scholar
• Kim HA, Jeon SH, Seo GY, et al. TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways. J Leukoc Biol. 2008;83(6):1431–1439. doi:10.1189/jlb.1007676.
   PubMed Web of Science ®Google Scholar
• Panchanathan R, Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol. 2013;53(1–2):15–23. doi:10.1016/j.molimm.2012.06.013.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Safety and efficacy of sifalimumab, an anti ifn-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum. 2014;66(Suppl10):L4. Abstract L4.
   Google Scholar
• Furie R, Merrill J, Werth V, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheumatol. 2015;67(Suppl10):S3865. Abstract 3223.
   Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. doi:10.1136/annrheumdis-2014-206090.
   PubMed Web of Science ®Google Scholar
• Hsu H, Khare SD, Lee F, et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol. 2012;30(2):197–201.
   PubMed Web of Science ®Google Scholar
• Kikly K, Manetta J, Smith H, et al. Characterization of LY2127399, A neutralizing antibody for BAFF. Arthritis Rheum. 2009;60(Suppl10):693.
   Google Scholar
• FDA Review of Benlysta: Pharmacology Review. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125370Orig1s000PharmR.pdf
   Google Scholar
• Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–3265. doi:10.1002/art.11299.
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215. doi:10.1186/s13075-015-0741-z.
   PubMed Web of Science ®Google Scholar
• Furie RA, Thomas M, Chu A, et al. Effects of blisibimod, an inhibitor of B cell activating factor, on serum immunoglobulins and infection risk in patients with systemic lupus erythematosus: observations from the placebo-controlled PEARL-SC and open-label extension studies. Arthritis Rheum. 2013;65(Suppl10):1742.
   Google Scholar
• 6159. FDA Review of Benlysta: Clinical Pharmacology and Biopharmaceutics Review. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125370Orig1s000ClinPharmR.pdf
   Google Scholar
• Scheinberg MA, Srinivasan D, Martin RS. The potential role of blisibimod for the treatment of systemic lupus erythematosus. Intl Journal Clinical Rheumatol. 2014;9(2):121–134. doi:10.2217/ijr.14.7.
   Google Scholar
• Goligher EC, Pouchot J, Brant R, et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol. 2008;35(4):635–642.
   PubMed Web of Science ®Google Scholar
• Golmia AP, Martin R, Hislop C, et al. Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy. Rheumatology. 2014;53(5):957–958. doi:10.1093/rheumatology/ket361.
   PubMed Web of Science ®Google Scholar
• Pike MC, Kelley L. Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? Curr Rheumatol Rep. 2012;14(4):324–333. doi:10.1007/s11926-012-0261-7.
   PubMed Web of Science ®Google Scholar
• Koyama A, Igarashi M, Kobayashi M. Members and coworkers of the research group on progressive renal diseases. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;4:526–532. doi:10.1016/S0272-6386(97)90333-4.
   Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, et al. Toronto glomerulonephritis registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177–3183. doi:10.1681/ASN.2007050526.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–1803. doi:10.1681/ASN.2011050464.
   PubMed Web of Science ®Google Scholar
• Linnik MD, Hu JZ, Heilbrunn KR, et al. Consortium, LJP 394 Investigator. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(4):1129–1137. doi:10.1002/art.20980.
   PubMed Web of Science ®Google Scholar
• Stohl W, Hiepe F, Latinis KM, et al. Group, BLISS-52 Study and Group, BLISS-76 Study. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–2337. doi:10.1002/art.34400.
   PubMed Web of Science ®Google Scholar